Pfizer, Inc. with ticker code (PFE) now have 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The range between the high target price and low target price is between 75 and 40 calculating the mean target price we have $52.06. Given that the stocks previous close was at $39.39 this indicates there is a potential upside of 32.2%. The day 50 moving average is $44.32 and the 200 moving average now moves to $47.61. The market capitalization for the company is $223,976m. Find out more information at: https://www.pfizer.com
The potential market cap would be $296,019m based on the market concensus.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
The company has a dividend yield of 4.16% with the ex dividend date set at 26-1-2023 (DMY).
Other points of data to note are a P/E ratio of 7.22, revenue per share of 17.89 and a 12.87% return on assets.